Fate Therapeutics, Inc. (FATE)
Fate Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Fate Therapeutics, Inc. (FATE) is a Biotechnology company based in US with a market capitalization of $329.9M. Revenue declined 51.2% year-over-year and free cash flow was negative at -$112M. This page tracks FATE's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 181 employees · IPO Oct 1, 2013
Valuation
Valuation & price
$1.75as of May 17, 2026· -43.6% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
1.59
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$329.9M
Market cap
-51.2%
Revenue growth (YoY)
-94.1%
Gross margin
-$112M
Free cash flow (USD)
-$125.8M
Net debt
Net cash position
4.5%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
2
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 13, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJun 15, 2026Filing
Stock Option Plan Amended
- 8-K eventJun 4, 2026Filing
Corporate Presentation
- Insider sellMay 21, 2026Filing
Insider Sell $54KValamehr Bahram · Director, President and CEO · $54.5K
- Insider sellMay 21, 2026Filing
Insider Sell $48KTAHL CINDY · See Remarks · $48.1K
- 8-K eventMay 13, 2026Filing
Earnings Release
- Quarterly reportMay 13, 2026Filing
10-Q Filed
Questions
Frequently asked questions
What is Fate Therapeutics, Inc.'s market cap?
Fate Therapeutics, Inc. (FATE) has a market capitalization of $329.9M.
What is FATE's P/E ratio?
A meaningful P/E ratio is not available for FATE — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is FATE's price-to-book (P/B) ratio?
FATE trades at 1.59 times book value per share.
Are insiders buying FATE stock?
SEC Form 4 filings show no open-market insider buys at Fate Therapeutics, Inc. in the last 90 days (2 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.